12,372 trials
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining — -3.96; -3.55 score on a scale
Opioid Dependence
Primary: Urine Toxicology for Opiate Use — 2; 4; 2; 0 Participants
Ankylosing Spondylitis
Primary: Percentage of Participants With no Radiographic Progression at Week 104 (Multiple Imputation) (Full Analysis Set) — 66.1; 66.9; 65.6 Percentage of participants — p=0.7164
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Overall Survival — 12.9; 11.6 months
Keratoconjunctivitis Sicca · Dry Eye
Primary: Change From Baseline in Eye Dryness Score as Measured by the VAS — -15.1; -20.6; -16.5 score on a scale — p=0.5533
Significant Bleeding Risk
Primary: Hemostatic Efficacy Rating by IEAB — 41; 50; 58; 47 Participants
Painful Diabetic Neuropathy · Diabetic Neuropathy, Painful
Primary: Long-term Safety for Engensis Versus Placebo — 10; 8; 1; 2 Participants
Postmenopausal Women With Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (LS-BMD) at Week 52 - Per-Protocol Set — 4.955; 5.099 Percentage change (%)
Atopic Dermatitis
Primary: Duration of Flare-Free Maintenance Until Onset of First-Flare During the Double Blind (DB) Period — 30; 111 Days — p=0.0034
Pain, Postoperative
Primary: Pain Visual Analog Scale (VAS) Score — 4.4; 5.7 score on a scale
Diabetic Macular Edema
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8 — 6.60; 6.56 BCVA letter score
Surgery
Primary: Measure Participants' Recovery Time Post-Surgery — 3.59; 3.62 hours
Heart Failure With Reduced Ejection Fraction
Primary: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 — -0.239; 0.207 mL/min/kg — p=0.13
Smoking · HIV
Primary: Number of Participants With 7-day Point Prevalence Abstinence at 36 Weeks — 5; 4; 1; 5 Participants